Clinical Trial: A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

U.S., March 12 -- ClinicalTrials.gov registry received information related to the study (NCT06869551) titled 'A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis' on March 06.

Brief Summary: The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Study Start Date: March 10

Study Type: INTERVENTIONAL

Condition: Juvenile Psoriatic Arthritis

Intervention: DRUG: Deucravacitinib

Specified dose on specified days

OTHER: Placebo

Specified dose on specified days

Recruitment Status: RECRUITING

Sponsor: Bristol-Myers Squibb

Publ...